{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:51:26Z","timestamp":1792014686784,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001170","name":"Cancer Council Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024253","name":"Western Australia Future Health Research and Innovation Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024253","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtocrr.2026.101049","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:23:44Z","timestamp":1783700624000},"page":"101049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["BAP1 Loss in Pleural Mesothelioma Is Associated With Reduced Soluble CCL2 in Patient Effusion, Abrogated CCL2-Mediated Monocyte Recruitment In Vitro"],"prefix":"10.1016","volume":"7","author":[{"given":"Alistair","family":"Nash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebony","family":"Rouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Firth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Dick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa S.","family":"Fear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Louw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.C. Gary","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec J.","family":"Redwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce W.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenette","family":"Creaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2026.101049_bib1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41571-022-00649-7","article-title":"Immunotherapy approaches for malignant pleural mesothelioma","volume":"19","author":"Fennell","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101049_bib2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/OP.21.00426","article-title":"Management of advanced pleural mesothelioma\u2014at the crossroads","volume":"18","author":"Nowak","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jtocrr.2026.101049_bib3","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/resp.12874","article-title":"Malignant pleural fluid from mesothelioma has potent biological activities","volume":"22","author":"Cheah","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.jtocrr.2026.101049_bib4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3233\/CBM-210280","article-title":"Profile of soluble factors in pleural effusions predict prognosis in mesothelioma","volume":"33","author":"Dick","year":"2022","journal-title":"Cancer Biomark"},{"key":"10.1016\/j.jtocrr.2026.101049_bib5","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00262-020-02773-8","article-title":"Prognostic significance of PD-1\/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters","volume":"70","author":"Singh","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jtocrr.2026.101049_bib6","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.3390\/cancers14153678","article-title":"BAP1 loss promotes suppressive tumor immune microenvironment via upregulation of PROS1 in Class 2 uveal melanomas","volume":"14","author":"Kaler","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jtocrr.2026.101049_bib7","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/2159-8290.CD-17-1246","article-title":"An empirical approach leveraging tumorgrafts to dissect the tumor microenvironment in renal cell carcinoma identifies missing link to prognostic inflammatory factors","volume":"8","author":"Wang","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtocrr.2026.101049_bib8","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","volume":"27","author":"Forde","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jtocrr.2026.101049_bib9","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111946118","article-title":"BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene \u00d7 environment interaction with asbestos","volume":"118","author":"Novelli","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtocrr.2026.101049_bib10","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jtho.2022.04.008","article-title":"BAP1 loss by immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: a validation study","volume":"17","author":"Louw","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2026.101049_bib11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ijc.2910470219","article-title":"Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions","volume":"47","author":"Manning","year":"1991","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtocrr.2026.101049_bib12","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtocrr.2026.101049_bib13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"10.1016\/j.jtocrr.2026.101049_bib14","doi-asserted-by":"crossref","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","article-title":"TIMER2. 0 for analysis of tumor-infiltrating immune cells","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jtocrr.2026.101049_bib15","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/onc.2015.243","article-title":"Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma","volume":"35","author":"Napolitano","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.jtocrr.2026.101049_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000228","article-title":"CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma","volume":"8","author":"Zhou","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtocrr.2026.101049_bib17","article-title":"BAP1 deficiency inflames the tumor immune microenvironment and is a candidate biomarker for immunotherapy response in malignant pleural mesothelioma","volume":"5","author":"Xu","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtocrr.2026.101049_bib18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ebiom.2019.09.003","article-title":"Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions","volume":"48","author":"Alcala","year":"2019","journal-title":"EBiomedicine"},{"key":"10.1016\/j.jtocrr.2026.101049_bib19","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.3390\/cancers14225626","article-title":"Isolated BAP1 genomic alteration in malignant pleural mesothelioma predicts distinct immunogenicity with implications for immunotherapeutic response","volume":"14","author":"Osmanbeyoglu","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jtocrr.2026.101049_bib20","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/JTO.0b013e31824c9272","article-title":"CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions","volume":"7","author":"Blanquart","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2026.101049_bib21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1165\/rcmb.2014-0017OC","article-title":"Tissue plasminogen activator potently stimulates pleural effusion via a monocyte chemotactic protein-1\u2013dependent mechanism","volume":"53","author":"Lansley","year":"2015","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jtocrr.2026.101049_bib22","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1186\/s12885-019-6419-1","article-title":"Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients","volume":"19","author":"Kishimoto","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtocrr.2026.101049_bib23","first-page":"E254","article-title":"Guidelines for the diagnosis and treatment of malignant pleural mesothelioma","volume":"5","author":"Van Zandwijk","year":"2013","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jtocrr.2026.101049_bib24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41525-020-00157-6","article-title":"Functional characterisation guides classification of novel BAP1 germline variants","volume":"5","author":"Hong","year":"2020","journal-title":"NPJ Genom Med"},{"key":"10.1016\/j.jtocrr.2026.101049_bib25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1158\/0008-5472.CAN-09-2326","article-title":"CCL2 blockade augments cancer immunotherapy","volume":"70","author":"Fridlender","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtocrr.2026.101049_bib26","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s42003-020-01441-y","article-title":"Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy","volume":"3","author":"Tu","year":"2020","journal-title":"Commun Biol"},{"key":"10.1016\/j.jtocrr.2026.101049_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jbo.2018.01.002","article-title":"Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer","volume":"11","author":"Wang","year":"2018","journal-title":"J Bone Oncol"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326001001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326001001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:21:08Z","timestamp":1792012868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364326001001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666364326001001"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101049","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BAP1 Loss in Pleural Mesothelioma Is Associated With Reduced Soluble CCL2 in Patient Effusion, Abrogated CCL2-Mediated Monocyte Recruitment In Vitro","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"101049"}}